Teddy Laboratory, a subsidiary of Tigermed, has officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services, establishing a comprehensive partnership that aims to transform the landscape of clinical trial services across China and international markets.
Strategic Partnership Framework
The agreement creates a dual-directional partnership structure where Teddy Laboratory will serve as LabConnect's preferred laboratory partner in China, providing lab services that meet international regulatory standards and supporting multinational pharmaceutical companies conducting clinical trials in China. Conversely, LabConnect will become Teddy Lab's preferred central lab partner for overseas operations, utilizing its extensive presence in key markets such as North America and Europe to help Chinese pharmaceutical companies expand globally.
The two parties will jointly build a full-chain laboratory service system covering both China and international markets to accelerate the development and commercialization of innovative drugs worldwide. This collaboration establishes what the companies describe as a complementary model of "China-based capabilities + global service network."
Leadership Perspectives
Jeff Mayhew, Chief Development Officer of LabConnect, emphasized the strategic value of the partnership, stating, "By fully leveraging our respective resources and technological strengths, we aim to further enhance global clinical trial service standards."
Ms. Xu Yi, Chairwoman of Teddy Laboratory/GuanHe Pharmaceuticals, highlighted the alignment between the companies' business models and their successful collaboration history. "LabConnect's unique business model aligns well with Teddy's localized strengths. Since our first Phase III clinical project together in 2022, we have successfully completed multiple international clinical trial collaborations," she stated at the signing ceremony.
Market Impact and Future Outlook
This strategic partnership represents a significant milestone in Teddy Laboratory's global expansion strategy and marks a deep integration of domestic and international central lab resources. The collaboration is designed to enhance global clinical trial service capabilities, support the development and launch of innovative drugs worldwide, and ultimately bring more advanced treatment options to patients.
The partnership builds upon an established working relationship between the two companies, with their collaboration dating back to 2022 when they completed their first Phase III clinical project together. Since then, they have successfully executed multiple international clinical trial collaborations, providing a foundation for this expanded strategic relationship.
